215511-39-0

Basic information

• Product Name: [(2S,5S,8S,23S)-2,5-Dibenzyl-8-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-3,6,14,17,24-pentaoxo-1,4,7,13,18-pentaaza-cyclotetracos-23-yl]-carbamic acid tert-butyl ester
• CAS NO: 215511-39-0
• Molecular Weight: 882.07
• Mol File: 215511-39-0.mol

Chemical Properties

• CAS DataBase Reference: [(2S,5S,8S,23S)-2,5-Dibenzyl-8-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-3,6,14,17,24-pentaoxo-1,4,7,13,18-pentaaza-cyclotetracos-23-yl]-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(2S,5S,8S,23S)-2,5-Dibenzyl-8-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-3,6,14,17,24-pentaoxo-1,4,7,13,18-pentaaza-cyclotetracos-23-yl]-carbamic acid tert-butyl ester(215511-39-0)
• EPA Substance Registry System: [(2S,5S,8S,23S)-2,5-Dibenzyl-8-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-3,6,14,17,24-pentaoxo-1,4,7,13,18-pentaaza-cyclotetracos-23-yl]-carbamic acid tert-butyl ester(215511-39-0)

Safety Data

• Hazardous Substances Data: 215511-39-0(Hazardous Substances Data)

Upstream product

• 215512-31-5 [(S)-1-((S)-1-{(S)-1-[(S)-5-Benzyloxycarbonylamino-1-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-pentylcarbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethylcarbamoyl)-5-(9H-fluoren-9-ylmethoxycarbonylamino)-pentyl]-carbamic acid tert-butyl ester 
• 215512-32-6 N-[(S)-5-((S)-1-{(S)-1-[(S)-5-Benzyloxycarbonylamino-1-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-pentylcarbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethylcarbamoyl)-5-tert-butoxycarbonylamino-pentyl]-succinamic acid 
• 1025993-54-7 N-[(S)-5-((S)-1-{(S)-1-[(S)-5-Amino-1-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-pentylcarbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethylcarbamoyl)-5-tert-butoxycarbonylamino-pentyl]-succinamic acid 

Relevant articles and documents

Synthesis and activity of HIV protease inhibitors

We report here the synthesis and activity of HIV protease inhibitors. In the first stage hydrophobic compounds incorporating a 'carba' bond surrogate or a beta-homologated residue were synthesized. Secondly, we synthesized cyclic compounds in which we incorporated 2-quinoline carboxylic acid in the P3 position and the amino-hydroxyindane moiety in the P'3. The last part of this work was dedicated to a structure/activity study of a peptide substrate. These modifications allowed us to work up the synthesis of new pseudopeptide bonds: amino-amide and hydroxy-amide. Compounds with activity in the micromolar range were actually a starting point for the synthesis of new protease inhibitors.